Azitra, Inc. AZTR
0.61 USD -0.02 (-3.03%)
Regular-session close
0.60 0.00 -0.69%
After hours · Nov 17, 5:50 PM ET
0.584 Day range 0.627
0.52 52-week range 3.91
- YTD
- -77.06%
- 1 year
- -82.06%
News
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Dare Bioscience (NASDAQ:DARE) shares rose 9.5% to $0.64 during Monday's after-market session. The company's market cap stands at $12.9 million. As per the press release, Q3 earnings came out…benzinga.com Anitra Q3 EPS $(0.29) Misses $(0.23) Estimate Anitra (AMEX:AZTR) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.23) by 31.82 percent. This is a 56.72 percent increase over losses of $(0.67) per…
prnewswire.com Azitra, Inc. Announces Q3 2026 Results and Provides Business Updates BRANFORD, Conn., Nov. 12, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies…benzinga.com Azitra To Present Pipeline Updates Including Results For ATR-COSF Program, Designed To Deliver Filaggrin Domains Into Human Skin To Reduce Appearance Of Fine Lines And Wrinkles, At BIO-Europe Initial results from first-in-human study with ATR-COSF anticipated by year-endBRANFORD, Conn., Nov. 10, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical-stage
prnewswire.com Azitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models Initial results from first-in-human study with ATR-COSF anticipated by year-end BRANFORD, Conn., Nov. 10, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a…benzinga.com Azitra Expands Eligibility For Ongoing Phase 1/2 Clinical Trial Of ATR04-484 To Include Individuals With Rash Associated With KRAS And MEK Inhibitors Expanded eligibility significantly broadens potential treatment opportunities for ATR-04 beyond EGFR inhibitor-associated skin rashAdditional protocol modifications expected to facilitate patient…
prnewswire.com Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors Expanded eligibility significantly broadens potential treatment opportunities for ATR-04 beyond EGFR inhibitor-associated skin rash Additional protocol modifications expected to facilitate patient…
benzinga.com Why Celestica Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket Celestica jumps 16.4% after beating Q3 FY26 estimates and raising guidance; 22nd Century leads premarket gainers at 69.8%.benzinga.com Azitra Suspends ATM Offering Program For The Foreseeable Future; From September 28, 2026 - October 26, 2026, The Company Sold An Aggregate Of 1,000 Shares Of Common Stock Under The ATM Program For Aggregate Gross Proceeds Of ~$126 ATM Program Effective October 26, 2026, the Company has decided not to utilize its at-the-market offering program (the "ATM Program") under the sales agreement, dated September 28, 2026, between the…
benzinga.com Azitra To Present Progress For Its Cosmetic ATR-COSF Program Targeting Fine Lines And Wrinkles At Bio-europe, November 10; First-In-Human Study With ATR-COSF Initial Results Anticipated By End Of 2026 ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin.Ex vivo data in two models of recent cosmetic surgery explants showed visible…
prnewswire.com Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin. Ex vivo data in two models of recent cosmetic surgery explants showed visible…
prnewswire.com Azitra, Inc. Announces Reverse Stock Split Common Stock Will Begin Trading on a Split-Adjusted Basis on October 26, 2026 BRANFORD, Conn., Oct. 16, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical…
prnewswire.com Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance BRANFORD, Conn., Oct. 1, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for…
defenseworld.net Azitra, Inc. (NYSEAMERICAN:AZTR) Sees Significant Drop in Short Interest Azitra, Inc. (NYSEAMERICAN:AZTR - Get Free Report) was the recipient of a large drop in short interest in September. As of September 15th, there was short interest totaling 701,345 shares, a drop of…
prnewswire.com Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference BRANFORD, Conn., Sept. 8, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies…
prnewswire.com Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards BRANFORD, Conn., Aug. 21, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies…
prnewswire.com Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates BRANFORD, Conn., Aug. 12, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies…
prnewswire.com Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a…
prnewswire.com Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond BRANFORD, Conn., June 17, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies…
prnewswire.com Azitra, Inc. to Present at 2026 BIO International Convention /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision
prnewswire.com Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting BRANFORD, Conn., June 4, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,…
prnewswire.com Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting BRANFORD, Conn., May 27, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,…
prnewswire.com Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates BRANFORD, Conn., May 13, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for…
prnewswire.com Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program Patent offers broad protections for ATR-12, an engineered strain of S. epidermidis that expresses a fragment of human LEKTI protein ATR-12 is currently the subject of a Phase 1b trial for the…
prnewswire.com Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris Preclinical data demonstrate ATR-01 delivers functional filaggrin, restoring skin barrier integrity and supporting advancement toward first-in-human studies BRANFORD, Conn., April 28, 2026…
benzinga.com Why Are Shares Of Azitra Rising? Azitra's spike is being fueled by a securities purchase agreement with healthcare-focused institutional investors for gross proceeds of up to $31.4 million, with Series B and C warrants exercisable…
feeds.benzinga.com Azitra Inc. (AZTR) Surges Over 44% After Hours— Here's Why It's Trending Azitra shares jumped over 44% in after-hours trading following a $31.4 million financing deal to advance its filaggrin protein and peptide platform.
